Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence

Journal of Psychiatry and Neuroscience

Volumn 31, Issue 1, 2006, Pages 38-45

  Dean, Angela J ^a,b,c   Saunders, John B ^a,b   Jones, Rod T ^b   Young, Ross M ^a,d   Connor, Jason P ^a   Lawford, Bruce R ^b,e  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c Kids in Mind Research   (Australia)

^d QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^e GREENSLOPES PRIVATE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CLONIDINE; DIAZEPAM; METHADONE; NALTREXONE; OCTREOTIDE; ONDANSETRON; OPIATE ANTAGONIST;

ADULT; ANALYSIS OF VARIANCE; ANESTHESIA; ANXIETY; ARTICLE; AUSTRALIA; BECK DEPRESSION INVENTORY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG COST; DRUG DETOXIFICATION; DYSPHORIA; FEMALE; FOLLOW UP; HEROIN DEPENDENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; METHADONE TREATMENT; NASOGASTRIC TUBE; ONSET AGE; OPEN STUDY; OPIATE ADDICTION; OPIATE TREATMENT INDEX; PATIENT COMPLIANCE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SOCIAL INTERACTION; STATE TRAIT ANXIETY INVENTORY;

ADULT; DEPRESSION; FEMALE; HEROIN DEPENDENCE; HUMANS; MALE; METHADONE; NALTREXONE; NARCOTIC ANTAGONISTS;

EID: 33644537364     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Volavka J, Resnick R, Kestenbaum R, et al. Short-term effects of naltrexone in 155 heroin ex-addicts. Biol Psychiatry 1976;11:679-85.
2. Sideroff S, Charuvastra V, Jarvik M. Craving in heroin addicts maintained on the opiate antagonist naltrexone. Am J Drug Alcohol Abuse 1978;5:415-23.
3. Judson B, Carney T, Goldstein A. Naltrexone treatment of heroin addiction: efficacy and safety in a double-blind dosage comparison. Drug Alcohol Depend 1981;7:325-46.
4. Farren CK, O'Malley S. A pilot double blind placebo controlled trial of sertraline with naltrexone in the treatment of opiate dependence. Am J Addict 2002;11:228-34.
5. Vining E, Kosten TR, Kleber HD. Clinical utility of rapid clonidine-naltrexone detoxification for opioid abusers. Br J Addict 1988;83:567-75.
6. Bartter T, Gooberman L. Rapid opiate detoxification. Am J Drug Alcohol Abuse 1996;22:489-95.
7. Brewer C. Ultra-rapid, antagonist-precipitated opiate detoxification under general anaesthesia or sedation. Addict Biol 1997;2/3:291-302.
8. O'Connor PG, Kosten TR. Rapid and ultrarapid opioid detoxification techniques. JAMA 1998;279:229-34.
9. Tretter F, Burkhardt D, Busello-Spieth B, et al. Clinical experience with antagonist-induced opiate withdrawal under anaesthesia. Addiction 1998;93:269-75.
10. Shufman EN, Porat S, Witztum E, et al. The efficacy of naltrexone in preventing reabuse of heroin after detoxification. Biol Psychiatry 1994;35:935-45.
11. Kirchmayer U, Davoli M, Verster A. Naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev 2003;(2):CD001333.
12. Tucker TK, Ritter AJ. Naltrexone in the treatment of heroin dependence: a literature review. Drug Alcohol Rev 2000;19:73-82.
13. D'Ippoliti D, Davoli M, Perucci CA, et al. Retention in treatment of heroin users in Italy: the role of treatment type and of methadone maintenance dosage. Drug Alcohol Depend 1998;52:167-71.
14. San L, Pomarol G, Peri JM, et al. Follow-up after a six-month maintenance period on naltrexone versus placebo in heroin addicts. Br J Addict 1991;86:983-90.
15. Tucker T, Ritter A, Maher C, et al. Naltrexone maintenance for heroin dependence: uptake, attrition and retention. Drug Alcohol Rev 2004;23:299-309.
16. Mendelson JH, Ellingboe J, Keuhnle JC, et al. Effects of naltrexone on mood and neuroendocrine function in normal adult males. Psychoneuroendocrinology 1978;3:231-6.
17. Hollister LE, Johnson K, Boukhabza D, et al. Aversive effects of naltrexone in subjects not dependent on opiates. Drug Alcohol Depend 1981;8:37-41.
18. Crowley T, Wagner J, Zerbe G, et al. Naltrexone-induced dysphoria in former opioid addicts. Am J Psychiatry 1985;142:1081-4.
19. Miotto K, McCann M, Rawson R, et al. Overdose, suicide attempts and death among a cohort of naltrexone-treated opioid addicts. Drug Alcohol Depend 1997;45:131-4.
20. Latt N, Jurd S, Houseman J, et al. Naltrexone in alcohol dependence: a randomised controlled trial of effectiveness in a standard clinical setting. Med J Aust 2002;176:530-4.
21. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-71.
22. Steer RA, Beck AT, Garrison B. Applications of the Beck Depression Inventory. In: Sartorius N, Bal. TA, editors. Assessment of depression. Berlin: Springer-Verlag; 1986. p. 123-42.
23. Spielberger CD, Gorsuch RL, Lushene R, et al. Manual for the State-Trait Anxiety Inventory (Form Y). Palo Alto (CA): Consulting Psychologist Press Inc.; 1983.
24. Darke S, Hall W, Wodak A, et al. Development and validation of a multi-dimensional instrument for assessing outcome of treatment among opiate users: the Opiate Treatment Index. Br J Addict 1992;87:733-42.
25. Hutchinson SJ, Taylor A, Gruer L, et al. One-year follow-up of opiate injectors treated with oral methadone in a GP-centred programme. Addiction 2000;95:1055-68.
26. Caplehorn JR, Bell J. Methadone dosage and retention of patients in maintenance treatment. Med J Aust 1991;154:195-9.
27. Rabinowitz J, Cohen H, Tarrasch R, et al. Compliance to naltrexone treatment after ultra-rapid opiate detoxification: an open label naturalistic study. Drug Alcohol Depend 1997;47:77-86.
28. Saunders JB, Jones R, Dean A, et al. Comparison of rapid opiate detoxification and naltrexone with methadone maintenance in the treatment of opiate dependence: a randomized controlled trial. Drug Alcohol Depend 2002;66(Suppl 1):S156.
29. Beck AT, Beamesderfer A. Assessment of depression: the depression inventory. Mod Probl Pharmacopsychiatry 1974;7:151-69.
30. Rea F, Bell JR, Young MR, et al. A randomised, controlled trial of low dose naltrexone for the treatment of opioid dependence. Drug Alcohol Depend 2004;75:79-88.
31. Krupitsky EM, Zvartau EE, Masalov DV, et al. Naltrexone for heroin dependence treatment in St. Petersburg, Russia. J Subst Abuse Treat 2004;26:285-94.
32. Croop RS, Faulkner EB, Labriola DF. The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. The Naltrexone Usage Study Group. Arch Gen Psychiatry 1997;54:1130-5.
33. Miotto K, McCann M, Basch J, et al. Naltrexone and dysphoria: Fact or myth? Am J Addict 2002;11:151-60.
34. Powell JE, Taylor D. Anger, depression, and anxiety following heroin withdrawal. Int J Addict 1992;27:25-35.
35. Handelsman L, Aronson MJ, Ness R, et al. The dysphoria of heroin addiction. Am J Drug Alcohol Abuse 1992;18:275-87.
36. Kanof PD, Aronson MJ, Ness R. Organic mood syndrome associated with detoxification from methadone maintenance. Am J Psychiatry 1993;150:423-8.
37. Ness R, Handelsman L, Aronson MJ, et al. The acute effects of a rapid medical detoxification upon dysphoria and other psychopathology experienced by heroin abusers. J Nerv Ment Dis 1994;182:353-9.
38. Elman I, D'Ambra MN, Krause S, et al. Ultrarapid opioid detoxification: effects on cardiopulmonary physiology, stress hormones and clinical outcomes. Drug Alcohol Depend 2001;61:163-72.
39. Dean AJ, Bell J, Mascord DJ, et al. A randomised, controlled trial of fluoxetine in methadone maintenance patients with depressive symptoms. J Affect Disord 2002;72:85-90.
40. Cacciola JS, Alterman AI, Rutherford MJ, et al. The relationship of psychiatric comorbidity to treatment outcomes in methadone maintained patients. Drug Alcohol Depend 2001;61:271-80.
41. Farren CK, O'Malley S. Occurence and management of depression in the context of naltrexone treatment of alcoholism. Am J Psychiatry 1999;156:1258-62.
42. Childress AR, Ehrman R, McLellan AT, et al. Can induced moods trigger drug-related responses in opiate abuse patients? J Subst Abuse Treat 1994;11:17-23.
43. Sideroff SI, Jarvik ME. Conditioned responses to a videotape showing heroin-related stimuli. Int J Addict 1980;15:529-36.
44. Rounsaville BJ, Weissman MM, Crits-Christoph K, et al. Diagnosis and symptoms of depression in opiate addicts. Course and relationship to treatment outcome. Arch Gen Psychiatry 1982;39:151-6.
45. Dean AJ, Bell J, Christie MJ, et al. Depressive symptoms during buprenorphine vs. methadone maintenance: findings from a randomised, controlled trial in opioid dependence. Eur Psychiatry 2004;19:510-3.
46. Nunes EV, Sullivan MA, Levin FR. Treatment of depression in patients with opiate dependence. Biol Psychiatry 2004;56:793-802.